Expression of P27, Ki67 and P53 in Squamous Cell Carcinoma, Actinic Keratosis and Bowen Disease

Abstract

This study aims at evaluating the expression of P27, Ki67 and P53 in Squamous Cell Carcinoma (SCC), Actinic Keratosis (AK) and Bowen Disease (BD) specimens. In an analytic-descriptive setting, skin biopsy specimens of 45 patients were evaluated in three 15-case groups including BD, AK and SCC specimens. Fifteen normal skin biopsy specimens were obtained and used as the control group. Immunohistochemical staining was performed in all the specimens and the expression rates and patterns of Ki67, P27 and P53 were determined. The results were compared between the four groups. Ki67 was expressed in 0.8, 23.7, 12.3 and 19.3% of the cells in the normal skin, AK, BD and SCC groups, respectively. No significant difference was seen between the three pathological conditions regarding the expression rate of Ki67. P27 was positive in 23.4, 26.2, 25.9 and 4.5% of specimens in the normal skin, AK, BD and SCC groups, respectively. This rate was significantly the lowest in the SCC group. P53 expression was detected in 26.6, 41.8 and 54.6% of the assessed cells in the AK, BD and SCC groups, respectively. There was no expression of P53 in the normal skin specimens. This rate was significantly the highest again in the SCC group. Based on these results, the quantitative and qualitative (pattern of distribution) evaluation of the expressions of Ki67, P27 and P53 may be helpful in differentiating malignant and premalignant epidermal lesions, particularly in unsatisfactory or fragmented specimens.

p53 immunoexpression in stepwise progression of cutaneous squamous cell carcinoma and correlation with angiogenesis and cellular proliferation

“…Cell proliferation, estimated by rate of Ki67-positive cells, is found to increase according to CSCC stages, from sun-exposed skin to SK [12], from normal skin to SCC [35] and from SK to iSCC [36]. However, some authors have found that Ki67 imunoexpression is higher in SK when compared to SCC [62][63][64], suggesting that Ki67 imunoexpression may not differentiate degree of CSSC malignancy. Interestingly, in the current study there were no significant differences in Ki67LI between groups.…”

Effectiveness and safety of 0·5% colchicine cream vs. photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratosis and skin field cancerization of the forearms: a randomized controlled trial

“…Ki67 nuclear expression has previously been studied in skin neoplasms and is seen in AK, Bowen disease, SCC and basal cell carcinoma. It indicates the epithelium proliferation rate and patterned expression in the epidermis for each neoplasm . To date, there is no study describing Ki67 expression in SFC activity.…”

In Silico Analysis Validates Proteomic Findings of Formalin-fixed Paraffin Embedded Cutaneous Squamous Cell Carcinoma Tissue

“…The ability to discriminate SCC variants based on distinct molecular profiles is of great importance when assessing the risk of progression, as well as the clinical management, of patients with cSCC (13). While immunohistochemistry and western blot studies have identified several abundant proteins differentially expressed between cSCC, actinic keratosis (AK) and Bowen's disease lesions, including cyclin-dependent kinase inhibitor 1B (p27), TP53 (14)(15)(16), serpin A1 (SERPINA1) (17); matrix metalloproteinase (MMP)-2, -7, -9 and -13 (16,18,19); c-myc protein (C-MYC) (20); tenascin-C (TNC) (21); and complement factor-I (CFI) and complement factor-H (CFH) (22,23), these markers have not been useful for classifying cSCC subtypes into clinically meaningful categories. The need for comprehensive molecular profiling of cSCC is clear (24).…”